Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized Study

Jeong, Chang Wook; Jeon, Hwang Gyun; Kwak, Cheol; Jeong, Hyeon; Lee, Sang Eun

doi:10.4143/crt.2005.37.1.44

Cited by 6 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, the combination of a cytotoxic agent with BCG could possibly contribute to enhanced binding, which in turn might explain the 100% tumour‐free survival in the present patients receiving combined therapy of BCG with a cytotoxic agent. Comparative studies on different dosages of mitomycin‐C, thiotepa and epirubicin reported no difference in recurrence rate, dose‐dependent response and concentration‐dependent response [26,27]. Further, there is no standard treatment duration or dose of these agents, and different groups have adopted different dosage schedules.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder

Saxena¹,

Agrawal²,

Agarwal³

et al. 2006

BJU International

View full text Add to dashboard Cite

OBJECTIVE To investigate the utility of an individualized chemo/immunotherapy regimen of intravesical therapy based on the results of an assessment of in vitro cytotoxicity. PATIENTS AND METHODS Intravesical adjuvant chemo/immunotherapy was given to 47 patients based on the results of in vitro cytotoxicity assay of the responses of cultured autologous tumour cells to various cytotoxic drugs (mitomycin‐C, doxorubicin and cisplatin) and immunomodulating agents (bacillus Calmette–Guérin, BCG and interferon‐α2b). Intravesical therapy was given as single‐ or double‐drug regimens according to the assay results: 16 (34%) patients showed cytotoxicity to a single drug and 31 (66%) showed maximum cytotoxicity to a combination of immunomodulators and cytotoxic agents. The efficacy of treatment in terms of tumour‐free survival and recurrence rate was compared with 40 patients receiving intravesical BCG according to International Protocol (control group). RESULTS In the in vitro assay group, seven patients (15%) had tumour recurrence, compared to 15 (38%) in the control group (P = 0.02). In the in vitro group, one of 16 patients on a single drug and six on the double‐drug regimen had a recurrence. The patients given BCG with cytotoxic drugs had no recurrences, but 29% of patients given interferon‐α2b combinations had recurrences. Kaplan–Meier analysis showed a longer recurrence‐free survival in the in vitro group (75%) than in the control group (49%) at 48 months of follow‐up. CONCLUSION Intravesical therapy based on an in vitro cytotoxicity assay is an attempt to give individualized therapy, and to increase tumour‐free survival in these patients, with no side‐effects. Recurrences in seven patients in the in vitro group might be due to a defective host immune response, or to expansion of a subclone of tumour cells resistant to all treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, no consensus on the optimum dosage was reached. When 30 mg and 40 mg instillations were compared there was little difference in recurrence‐free rates [26]; the recurrence rates reported for mitomycin‐C after 1.5 years of follow‐up were 19% and 24% in the 30‐mg group, and 12% and 24% in the 40‐mg group.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder

Saxena¹,

Agrawal²,

Agarwal³

et al. 2006

BJU International

View full text Add to dashboard Cite

show abstract

“…[1][2][3]11 Pemberian obat intravesika yang banyak digunakan adalah mitomycin C (MMC), doxorubicin, dan Bacillus Calmette-Guerin (BCG). 1,2,16 Pemberian BCG intravesika bersifat imunoterapi dengan menekan rekurensi serta progresifitas dari karsinoma kandung kemih sehingga diindikasikan untuk penderita-penderita yang cenderung mengalami kekambuhan setelah operasi reseksi transuretral. 1,12,16 BCG mengurangi kekambuhan 40% -45%, dibanding obat intravesika lain yang hanya sebesar 8-18%.…”

Section: Gambar 2 Gambaran Ultrasonografi Yang Menunjukkan Suatu Polunclassified

“…1,2,16 Pemberian BCG intravesika bersifat imunoterapi dengan menekan rekurensi serta progresifitas dari karsinoma kandung kemih sehingga diindikasikan untuk penderita-penderita yang cenderung mengalami kekambuhan setelah operasi reseksi transuretral. 1,12,16 BCG mengurangi kekambuhan 40% -45%, dibanding obat intravesika lain yang hanya sebesar 8-18%. 2,16 Pada beberapa penelitian penggunaan MMC dosis minimal sebagai kemoterapi intravesika telah menunjukkan efektifitas yang sangat tinggi terhadap karsinoma kandung kemih.…”

Section: Gambar 2 Gambaran Ultrasonografi Yang Menunjukkan Suatu Polunclassified

“…1,12,16 BCG mengurangi kekambuhan 40% -45%, dibanding obat intravesika lain yang hanya sebesar 8-18%. 2,16 Pada beberapa penelitian penggunaan MMC dosis minimal sebagai kemoterapi intravesika telah menunjukkan efektifitas yang sangat tinggi terhadap karsinoma kandung kemih. Selain itu tidak mengakibatkan efek samping yang serius.…”

Section: Gambar 2 Gambaran Ultrasonografi Yang Menunjukkan Suatu Polunclassified

See 1 more Smart Citation

Karsinoma Kandung Kemih

Senduk

Rotty

2013

JBM

View full text Add to dashboard Cite

We reported a case of bladder carcinoma in a male of 65 years. The main complaints were hematuria, urinary frequency, dysuria, urgency, loss of weight, and pain in the genital area spreading to the lower abdomen. Diagnosis made by clinical, laboratory, and cytological examinations had no result. Final diagnosis was made by ultrasonography and cystoscopy, associated with transurethral biopsy and histopathological examination. The result was papillary transitional cell carcinoma, class II; and according to TNM it was a superficial bladder carcinoma in stadium at least T1. Transurethral resection of the tumor was done, and intravesical medicine was given (mitomycin C 40 mg once a week for 6 weeks). The patient was advised to stop smoking and drinking coffee. The prognosis was good. Key words: hematuria, bladder tumor, USG, cystoscopy, tansurethral resection. Abstrak: Telah dilaporkan kasus karsinoma kandung kemih pada seorang laki-laki berusia 66 tahun. Keluhan utama: hematuri, urgensi, disuri, frekuensi, penurunan berat badan, dan nyeri di kemaluan sampai perut bagian bawah. Diagnosis yang ditegakkan berdasarkan pemeriksaan klinis, laboratorium, sitologi tidak memberi hasil positif. Diagnosis pasti ditegakkan berdasar-kan ultrasonografi dan sistoskopi, disertai biopsi transuretral dan pemeriksaan histopatologi. Hasil yang diperoleh karsinoma sel transisional papiler kelas II, dan berdasarkan TNM sebagai karsinoma kandung kemih superfisial dengan stadium sekurang-kurangnya T1. Penanganan yang dilakukan adalah reseksi tumor transuretral yang diikuti pemberian obat intravesika (mitomicyn C 40 mg sekali seminggu selama 6 minggu), dan penderita dianjurkan untuk berhenti merokok dan berhenti minum kopi. Prognosis penderita ini baik. Kata kunci: hematuria, tumor kandung kemih, USG, sistoskopi, reseksi transuretral.

show abstract

The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

Scilipoti,

Ślusarczyk,

de Angelis

et al. 2024

European Urology Oncology

View full text Add to dashboard Cite

Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized Study

Cited by 6 publications

References 13 publications

Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder

Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder

Karsinoma Kandung Kemih

The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About